MiNK Therapeutics, Inc. SEC filings INKT
MiNK Therapeutics, Inc. has 265 filings in SEC EDGAR's recent list, going back to Jan 22, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 13, 2026 | — |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 17, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Mar 27, 2026 | Mar 27, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 19, 2026 | Mar 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 29, 2025 |
| EFFECT | Filing | Dec 11, 2025 | — |
| CORRESP | Letter to the SEC | Dec 10, 2025 | — |
| S-3/A | Filing | Dec 10, 2025 | — |
| 8-K |
Current report
Results of operations
|
Dec 8, 2025 | Nov 14, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| S-3 | Shelf registration | Nov 7, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2025 | Sep 23, 2025 |
| 424B5 | Prospectus supplement | Aug 22, 2025 | — |
| S-8 | Employee stock plan registration | Aug 14, 2025 | — |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2025 | Aug 14, 2025 |
| 8-K |
Current report
Material agreement
|
Jul 15, 2025 | Jul 15, 2025 |
| 424B5 | Prospectus supplement | Jul 15, 2025 | — |
| 8-K |
Current report
Other events
|
Jul 14, 2025 | Jul 11, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2025 | Jun 18, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 15, 2025 | May 15, 2025 |
| ARS | Annual report to shareholders | Apr 30, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 30, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 18, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 18, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jan 21, 2025 | Jan 17, 2025 |
| DEF 14A | Proxy statement | Dec 20, 2024 | Jan 17, 2025 |
| PRE 14A | Preliminary proxy statement | Dec 6, 2024 | Jan 17, 2025 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 31, 2024 | Oct 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 18, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Listing notice
|
Sep 13, 2024 | Sep 13, 2024 |
| 8-K |
Current report
Listing notice
|
Aug 30, 2024 | Aug 27, 2024 |
| EFFECT | Filing | Aug 16, 2024 | — |
| 424B3 | Prospectus | Aug 16, 2024 | — |
| CORRESP | Letter to the SEC | Aug 15, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2024 | — |
| S-3 | Shelf registration | Aug 13, 2024 | — |
| S-8 | Employee stock plan registration | Aug 13, 2024 | — |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2024 | Jun 12, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 16, 2024 | May 13, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| ARS | Annual report to shareholders | Apr 30, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Listing notice
|
Feb 29, 2024 | Feb 23, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Feb 14, 2024 | Feb 12, 2024 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Oct 17, 2023 | Oct 12, 2023 |
| S-8 | Employee stock plan registration | Aug 11, 2023 | — |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 20, 2023 | Jun 13, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| DEF 14A | Proxy statement | May 1, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 24, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2023 | Mar 21, 2023 |
| EFFECT | Filing | Nov 8, 2022 | — |
| CORRESP | Letter to the SEC | Nov 7, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2022 | — |
| S-3 | Shelf registration | Nov 3, 2022 | — |
| 8-K |
Current report
Results of operations
|
Nov 3, 2022 | Nov 3, 2022 |
| 10-Q | Quarterly report | Nov 3, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 15, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K |
Current report
Material agreement
|
Aug 5, 2022 | Aug 2, 2022 |
| S-8 | Employee stock plan registration | Jul 15, 2022 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 14, 2022 | Jun 8, 2022 |
| 10-Q | Quarterly report | May 13, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 8, 2022 |
| 10-K | Annual report | Mar 18, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Officer or director change
|
Mar 8, 2022 | Mar 2, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 6, 2022 | Dec 31, 2021 |
| 10-Q | Quarterly report | Nov 29, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Oct 20, 2021 | Oct 19, 2021 |
| 424B4 | Prospectus | Oct 15, 2021 | — |
| FWP | Free writing prospectus | Oct 15, 2021 | — |
| EFFECT | Filing | Oct 14, 2021 | — |
| CERT | Filing | Oct 14, 2021 | — |
| 8-A12B | Filing | Oct 13, 2021 | — |
| CORRESP | Letter to the SEC | Oct 12, 2021 | — |
| CORRESP | Letter to the SEC | Oct 12, 2021 | — |
| S-1/A | Amended registration statement | Oct 12, 2021 | — |
| CORRESP | Letter to the SEC | Sep 24, 2021 | — |
| S-1 | Registration statement | Sep 14, 2021 | — |
| CORRESP | Letter to the SEC | Sep 13, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2021 | — |
| DRSLTR | Filing | Jul 28, 2021 | — |
| DRS/A | Filing | Jul 28, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2021 | — |
| DRS/A | Filing | Mar 18, 2021 | — |
| DRSLTR | Filing | Mar 17, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 22, 2021 | — |
| DRS | Filing | Jan 22, 2021 | — |
Showing 112 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1840229
- Former names
- AgenTus Therapeutics, Inc. (until Mar 18, 2021); AgenTus Therapeutics, Inc. (until Mar 18, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.